The use of psychedelic agents in the management of mental health disorders

Expert/s: Rick Doblin

Listen to the episode

Description

In this episode:

  • The effect size and enduring benefit of MDMA in PTSD has surpassed all expectation in Phase 3 trials
  • It is possible this agent may be approved by the FDA pending the results of the second Phase 3 trial which is now underway

 

Host: Dr David Lim, GP and Medical Educator

Total time: 40 mins

Guest: Rick Doblin, Founder and Executive Director

 

Recommended Resources:

 

Last Updated: 9 Nov, 2021

Further your CPD learning

Based on this educational activity, complete these learning modules to gain additional CPD.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Andrew Sindone

Prof Andrew Sindone

Heart Failure – Demystifying Pharmacological Management for GPs

Dr Rupert Hinds

Dr Rupert Hinds

Iron Deficiency in Children & Young People

Speaker TBA

Speaker TBA

Heart Failure – Assessment and Monitoring in Primary Care

Prof Dave Singh

Prof Dave Singh

COPD Update

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Rick Doblin

expert

Rick Doblin

Founder and Executive Director; the Multidisciplinary Association for Psychedelic Studies (MAPS), USA

Recent articles

Share this

You have completed the Educational Activities component of this resource. 

Select ‘Confirm & claim CPD‘ to confirm you have engaged with this resource in its entirety and claim your CPD.

You will be taken to explore further CPD learning available to you.